Black Diamond Therapeutics reported its financial results for the second quarter ended June 30, 2025, on August 7, 2025. The company recorded a net loss of $10.6 million for the quarter. This financial update follows a period of strategic adjustments and a significant licensing deal earlier in the year.
A key operational milestone was achieved with the completion of enrollment in the silevertinib (BDTX-1535) Phase 2 trial for the treatment of newly diagnosed patients with EGFRm NSCLC. This completion sets the stage for an anticipated clinical update in the fourth quarter of 2025.
The company also announced it is exploring partnership opportunities to advance silevertinib into pivotal development. This strategy aims to accelerate the delivery of this potential treatment to patients, considering the evolving competitive and regulatory landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.